RT EU Medicines Agency
EMA’s #safety committee, the #PRAC, is reviewing data on the risk of suicidal thoughts and thoughts of self-harm with GLP-1 receptor agonists used for weight loss and for treating type 2 #diabetes.
Read more in the news announcement: https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists https://t.co/Rf3Ly9FGbM

🐦🔗: https://n.respublicae.eu/EMA_News/status/1678794781256761346

EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-july-2023
#SafetyOfMedicines https://t.co/D0EHywwIMF

🐦🔗: https://n.respublicae.eu/EMA_News/status/1677261762968662016

At its June meeting, EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.

More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-june-2023

#SafetyOfMedicines

🐦🔗: https://n.respublicae.eu/EMA_News/status/1667127819984306176

If an unusual pattern emerged, the #PRAC performed an in-depth analysis of the reports to quickly identify potential safety issues with #Covid19vaccines.

The 🇪🇺 pharmacovigilance system showed that it can detect and manage emerging #safety issues quickly.

#EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1666080058241581057

We placed extra obligations on the #Covid19vaccine makers.

They had to provide us with detailed monthly reports on the #safety of their vaccine ➡️ 5⃣6⃣monthly reports were assessed by our safety committee, the #PRAC, until December 2022.

#EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1666079498784366597

EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.

More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-march-2023

#SafetyOfMedicines

🐦🔗: https://n.respublicae.eu/EMA_News/status/1636691621998673920

At its February meeting, EMA's safety committee, the #PRAC, started a safety review of medicines containing pseudoephedrine.

#PublicHealth #SafetyOfMedicines

➡️ https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-february-2023

🐦🔗: https://n.respublicae.eu/EMA_News/status/1624037832950939650

At its January meeting, our safety committee 🔎💊, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.

#chronicillness #SafetyOfMedicines

Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023

🐦🔗: https://n.respublicae.eu/EMA_News/status/1613886224040710148

RT @EMA_News: At its January meeting, our safety committee 🔎💊, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.

#chronicillness #SafetyOfMedicines

Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023

🐦🔗: https://n.respublicae.eu/Food_EU/status/1613888043802394627

The #PRAC recommended measures to minimise risk of serious #sideeffects with Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic

🐦🔗: https://nitter.eu/EMA_News/status/1585941029844582400

The #PRAC confirmed its recommendation to withdraw the marketing authorisations for #amfepramone medicines 💊
https://www.ema.europa.eu/en/news/ema-confirms-recommendation-withdraw-marketing-authorisations-amfepramone-medicines

🐦🔗: https://nitter.eu/EMA_News/status/1585941027365752832

At its November meeting, our #safety committee, the #PRAC, recommended the addition of heavy menstrual bleeding as a side effect of the mRNA #COVID19 vaccines.

Most cases reviewed were non-serious and temporary.

Read the highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-24-27-october-2022

🧵

🐦🔗: https://nitter.eu/EMA_News/status/1585941023355637761

Our #safety committee, the #PRAC, has recommended:
➡️measures for terlipressin-containing medicines in the treatment of people with advanced liver disease & kidney problems
➡️adding a warning when using codeine with ibuprofen at higher than recommended doses for prolonged periods

🐦🔗: https://nitter.eu/EMA_News/status/1575799367839219713

Our #safety committee, the #PRAC, has recommended:
➡️measures for terlipressin-containing medicines in the treatment of people with advanced liver disease & kidney problems
➡️adding a warning when using codeine with ibuprofen at higher than recommended doses for prolonged periods

🐦🔗: https://nitter.eu/EMA_News/status/1575799367839219713

Our #safety committee, the #PRAC, has started 2 reviews:
➡️ one for #topiramate use in pregnancy and the risk of neurodevelopmental disorders in children
➡️ one for #pholcodine-containing medicines due to concerns about the risk of developing severe allergy to other medicines

🐦🔗: https://nitter.eu/EMA_News/status/1565689936702996481

Our #safety committee, the #PRAC, recommended new measures to minimise the risk of #meningioma with 💊 containing #nomegestrol or #chlormadinone.
It also started a review of risks of neurodevelopmental disorders with #topiramate.
👉https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-4-7-july-2022

🐦🔗: https://nitter.eu/EMA_News/status/1545355046187110406

EMA's #safety committee, the #PRAC, has recommended withdrawal of marketing authorisations for amfepramone obesity drugs.

While evaluation of heavy menstrual bleeding cases with #COVID19 mRNA vaccines continues, no link found between these vaccines & absence of menstruation.

🐦🔗: https://nitter.eu/EMA_News/status/1535288570335870977

EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.💊

🔎 Find all safety reviews under evaluation in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-may-2022

#SafetyOfMedicines

🐦🔗: https://nitter.eu/EMA_News/status/1522542450744639489

EMA's safety committee, the #PRAC, finds no link between mRNA #COVID19vaccines and very rare cases of autoimmune hepatitis.

👉 https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-4-7-april-2022

#SafetyOfVaccines

🐦🔗: https://nitter.eu/EMA_News/status/1512384277803147264

RT @EMA_News: EMA's safety committee, the #PRAC, finds no link between mRNA #COVID19vaccines and very rare cases of autoimmune hepatitis.

👉 https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-4-7-april-2022

#SafetyOfVaccines

🐦🔗: https://nitter.eu/EU_Health/status/1512384427078340611